Cancer/Tumor Profiling Market by Technology, Biomarker Type, Cancer Type, Application

Description

List of Tables

[199 Pages Report] The Cancer/Tumor Profiling Market size was estimated at USD 10.79 billion in 2023 and expected to reach USD 12.77 billion in 2024, at a CAGR 18.74% to reach USD 35.94 billion by 2030.

Cancer/tumor profiling is a laboratory method that analyzes specific proteins, genes, and other molecules in a tumor to provide information about any genetic or molecular changes, such as gene mutations. Tumor profiling is the technology that oncologists widely use to determine if the pathways of a patient's tumor match up with available targeted treatments. Accelerated use of biomarkers in the treatment of cancer patients and increasing preference for customized cancer treatments coupled with government and international organization's efforts to develop cancer diagnosis methods support the widespread use of cancer/tumor profiling technologies. On the other hand, high capital investment in cancer/tumor profiling tools and services and low biomarker discovery-to-approval ratio hinders market development. However, the spread of next-generation sequencing, tumor profiling improvements, and point-of-care cancer detection technology expansion is expected to surge their use in the coming years.

KEY MARKET STATISTICS
Base Year [2023]	USD 10.79 billion
Estimated Year [2024]	USD 12.77 billion
Forecast Year [2030]	USD 35.94 billion
CAGR (%)	18.74%

Technology: Adoption of next-generation sequencing (NGS) for exploring genetic alterations in various cancers

Immunoassays dominate the technology segment of the cancer tumor profiling market owing to rising applications in conducting tumor profiling on a large scale, as they aid in measuring the presence and concentration of analytes in a sample. In situ hybridization (ISH), including fluorescence in-situ hybridization (FISH) and chromogenic in situ hybridization (CISH), uses labeled complementary DNA or RNA strands to localize a specific DNA or RNA sequence on a chromosome or section of tissue (in-situ) fixed on a slide. FISH profiling is less time-consuming than conventional approaches and assists in easy chromosomal microdeletion, amplification, and translocation. Mass spectrometry-based cancer/tumor profiling is increasingly used in cancer research to detect subtle changes in proteome and metabolome. In contrast, microarrays are widely used to understand cancer cells' genetic and epigenetic makeup, and they are utilized to identify small genetic changes in tumor cells. The development of next-generation sequencing (NGS) helps in effectively exploring genetic alterations in various cancers and identifying several genetic or epigenetic variants to develop new biomarkers for early diagnosis of the disease. Polymerase chain reaction (PCR) is used to look for specific changes in a gene or chromosome, which helps find and diagnose a genetic condition or a disease, such as cancer. Moreover, technological advances in imaging and biochemical processes that allow earlier detection of a metastatic lesion could yield higher success rates in cancer therapy.

Biomarker Type: Use of genomic biomarkers for the measurement of the expression of a gene, the gene function, and the gene regulation

Genomic biomarkers can be termed as the measurement of the expression of a gene, the gene function, or the gene regulation, and testing can determine whether someone's cancer has an estimated glomerular filtration rate (EGFR) gene mutation that can be treated with an EGFR inhibitor and also helps study a new cancer treatment in a clinical trial. An ideal cancer biomarker can be a protein or protein fragment that is easy to detect in the patient's blood or urine except for a healthy patient. In addition, there are many cancer biomarkers, and they separately work within the body and react differently to treatments. These cancer biomarkers can also include gene mutations (changes), gene rearrangements, extra copies of genes, missing genes, and several other molecules.

Cancer Type: Wide preference for cancer profiling in prostate cancers for predictive modeling and clinical risk stratification

Cancer/tumor profiling has become an integral part of disease management on multiple levels for breast cancer. Genetic testing identifies hereditary cancer syndromes in patients with a family history of malignancies and contributes to successful breast cancer prevention. Molecular profiling of colorectal cancer (CRC) has the advantage of providing essential information on the pathogenesis of cancer and also about the targeted therapy. The landscape of metastatic CRC (mCRC) treatment is changing with an understanding of its heterogeneity and molecular blueprint, although chemotherapy remains the backbone of treatment. Common genetic mutations in lung cancer, such as estimated glomerular filtration rate (EGFR), RET, MET, BRAF, and anaplastic lymphoma kinase (ALK), can be detected, which leads to offering targeted therapy to the patient. Molecular predictive tests based on gene expression profiling (GEP) of cutaneous melanoma (CM) are susceptible and have the potential to predict biological behavior. Moreover, cancer/tumor profiling of prostate cancer has more recently emerged as a reliable method for predictive modeling and clinical risk stratification. Integrative genomic profiling of prostate tumors has provided comprehensive information and novel discoveries that improve understanding of the disease in the new era of precision medicine.

Application: Increasing use of cancer/tumor profiling in developing precision medicine to improve healing and recovery time

Cancer/tumor profiling has significantly advanced clinical oncology by identifying therapeutic targets and molecular biomarkers, guiding the personalization of cancer treatment with remarkably improved outcomes for numerous common and rare tumor entities. Cancer/tumor profiling is normally used in developing precision medicine that suits a patient's genetic makeup to improve healing and recovery time. The upgradation of biomarker discovery and development with the application of new and complex technologies and more clinical applications of biomarkers improves diagnosis, prognosis, and disease monitoring. Researchers are touting more precision-based and targeted techniques to streamline cancer treatment, which propels rapid diagnostics providers to seek highly sophisticated cancer profiling approaches. Genome-based prognostic biomarkers are used in the prognosis of several cancer types at clinical stages and also help develop drugs and therapies. Cancer/tumor profiling is also helpful in cancer screening and can help in early detection, management, and, potentially, curing cancer. In addition, cancer/tumor profiling offers the sensitive and accurate detection of biomarkers and has a reliable approach for noninvasive disease diagnosis and treatment response monitoring.

Regional Insights

Cancer/tumor profiling market landscape in North America, the EU, GCC, and developed countries across the Asia-Pacific region are highly advanced due to prominent market players and well-established regulatory frameworks and initiatives launched by the governments to reduce cancer burden while improving patient care. Cancer profiling is gradually gaining prominence in developing economies worldwide as investments in cancer diagnostics continue to rise. According to the American Cancer Society, approximately 1.9 million new cancer cases are anticipated to be diagnosed in the United States in 2023, bolstering the need for cancer profiling. Northern and Western European countries observe considerably high use and availability of biomarker testing procedures, refiecting their higher investment in healthcare. Market players across countries are collaborating with technology providers in the United States and European countries and each other to contribute to deploying the advancement in cancer diagnosis, profiling, and treatment procedures. Furthermore, the ongoing campaigns and cancer awareness programs have highlighted the need for cancer/tumor profiling in Asian countries.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Cancer/Tumor Profiling Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cancer/Tumor Profiling Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Cancer/Tumor Profiling Market, highlighting leading vendors and their innovative profiles. These include 4basecare Onco Solutions Private Limited, ACT Genomics Co., Ltd. by Prenetics Global Limited, Agendia, Inc., Agilent Technologies, Inc., BostonGene Corporation, Caris Life Sciences, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., GENINUS Inc., Genomic Life, GenScript Biotech Corporation, Guardant Health, Inc., Hologic, Inc., HTG Molecular Diagnostics, Inc., Illumina, Inc., IMBdx, Inc., Laboratory Corporation of America Holdings, Lucence Health, Inc., Merck KGaA, NanoString Technologies, Inc., Neogenomics, Inc., Nonacus Limited, OncoDNA S.A., Oncompass Medicine Hungary Kft., Paragon Genomics, Inc., Personalis, Inc., Perthera, Inc., Predictive Oncology Inc., Strand Life Sciences, Sysmex Corporation, Takara Bio Inc., Tempus Labs Inc., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Cancer/Tumor Profiling Market to forecast the revenues and analyze trends in each of the following sub-markets:

Technology
- Immunoassays
- In-Situ Hybridization
- Mass Spectrometry
- Microarrays
- Next-Generation Sequencing
- Polymerase Chain Reaction

Biomarker Type
- Genomic Biomarker
- Protein Biomarker

Cancer Type
- Breast Cancer
- Colorectal Cancer
- Lung Cancer
- Melanoma Cancer
- Prostate Cancer

Application
- Biomarker Discovery
- Clinical Application
- Diagnostics
- Personalized Medicine
- Prognostics
- Research
- Screening
- Treatment & Monitoring

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Cancer/Tumor Profiling Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cancer/Tumor Profiling Market?

3. What are the technology trends and regulatory frameworks in the Cancer/Tumor Profiling Market?

4. What is the market share of the leading vendors in the Cancer/Tumor Profiling Market?

5. Which modes and strategic moves are suitable for entering the Cancer/Tumor Profiling Market?

Product Code: MRR-374DB5A06C7F

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing adoption of biomarkers to treat cancer patients
  - 5.1.1.2. Availability of government and global organizations' initiatives for devising cancer diagnosing methods
  - 5.1.1.3. Surging preference for personalized medicines for cancer treatment
- 5.1.2. Restraints
  - 5.1.2.1. High capital investment in cancer/tumor profiling instruments and services
- 5.1.3. Opportunities
  - 5.1.3.1. Emergence of next-generation sequencing and advancements in tumor profiling
  - 5.1.3.2. Improvements in point-of-care diagnostic technologies to improve cancer detection
- 5.1.4. Challenges
  - 5.1.4.1. Low biomarker discovery-to-approval ratio
5.2. Market Segmentation Analysis
- 5.2.1. Technology: Adoption of next-generation sequencing (NGS) for exploring genetic alterations in various cancers
- 5.2.2. Biomarker Type: Use of genomic biomarkers for the measurement of the expression of a gene, the gene function, and the gene regulation
- 5.2.3. Cancer Type: Wide preference for cancer profiling in prostate cancers for predictive modeling and clinical risk stratification
- 5.2.4. Application: Increasing use of cancer/tumor profiling in developing precision medicine to improve healing and recovery time
5.3. Market Trend Analysis
- 5.3.1. Government initiatives for cancer diagnostics with rapid advancements in cancer/tumor profiling solutions
- 5.3.2. Rising cancer prevalence with evolving cancer research initiatives enhancing the need for novel cancer/tumor profiling in the APAC region
- 5.3.3. Increasing adoption of precision medicines and genetic profiling solutions to overcome the cancer burden across EMEA region
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework Analysis

6. Cancer/Tumor Profiling Market, by Technology

6.1. Introduction
6.2. Immunoassays
6.3. In-Situ Hybridization
6.4. Mass Spectrometry
6.5. Microarrays
6.6. Next-Generation Sequencing
6.7. Polymerase Chain Reaction

7. Cancer/Tumor Profiling Market, by Biomarker Type

7.1. Introduction
7.2. Genomic Biomarker
7.3. Protein Biomarker

8. Cancer/Tumor Profiling Market, by Cancer Type

8.1. Introduction
8.2. Breast Cancer
8.3. Colorectal Cancer
8.4. Lung Cancer
8.5. Melanoma Cancer
8.6. Prostate Cancer

9. Cancer/Tumor Profiling Market, by Application

9.1. Introduction
9.2. Biomarker Discovery
9.3. Clinical Application
9.4. Diagnostics
9.5. Personalized Medicine
9.6. Prognostics
9.7. Research
9.8. Screening
9.9. Treatment & Monitoring

10. Americas Cancer/Tumor Profiling Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Cancer/Tumor Profiling Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Cancer/Tumor Profiling Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
- 13.3.1. Agilent and NCCS Sign Research Collaboration Agreement to Advance Singapore's Genomic Profiling on Asian-prevalent Cancers
- 13.3.2. Sophia Genetics, Agilent Partner on Cancer Analysis Product
- 13.3.3. Point32Health and Foundation Medicine Expand Access to Comprehensive Genomic Profiling for Members with Advanced Cancer
- 13.3.4. Synergy Laboratories Taps SOPHiA GENETICS Technology for New Cancer Profiling Solution
- 13.3.5. Exact Sciences Launches OncoExTra Cancer Therapy Selection Test in the U.S.
- 13.3.6. Caris Life Sciences nears USD 2B in total funding with USD 400M haul
- 13.3.7. Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco
- 13.3.8. Agilent Announces Acquisition of Avida Biomed, Developer of High-Performance NGS Target Enrichment Workflows for Cancer Research
- 13.3.9. Prenetics Acquires ACT Genomics
- 13.3.10. Roche receives FDA approval for first companion diagnostic to identify patients with HER2 low metastatic breast cancer eligible for Enhertu
- 13.3.11. CDC Awards USD 215 Million to Advance Cancer Moonshot Goals

14. Competitive Portfolio

14.1. Key Company Profiles
14.2. Key Product Portfolio